The four Janus kinase (JAK) proteins and seven signal transducer and activator of
transcription (STAT) transcription factors mediate intracellular signal transduction …

Janus kinase (JAK) is a family of cytoplasmic non-receptor tyrosine kinases that includes
four members, namely JAK1, JAK2, JAK3, and TYK2. The JAKs transduce cytokine signaling …

Objective To evaluate the efficacy, including capacity for inhibition of radiographic
progression, and safety of upadacitinib, a JAK 1‐selective inhibitor, as compared to placebo …

The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts
to target their associated signalling pathways. Janus kinases (JAKs) are essential signalling …

Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …

The Janus kinase/signal transduction and activator of transcription (JAK–STAT) signaling
pathway is implicated in the pathogenesis of inflammatory and autoimmune diseases …

Objective To develop a new evidence‐based, pharmacologic treatment guideline for
rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the …

Janus kinase (JAK) Inhibitors are the latest drug class of disease-modifying medication to
emerge for the treatment of rheumatoid arthritis (RA). They are a small molecule-targeted …

Background Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the
treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic …

Background Final data are presented for the ORAL Sequel long-term extension (LTE) study
evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 …